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Abstract
Background: Endothelial E-selectin has been shown to play a pivotal role in mediating cell–cell interactions between breast
cancer cells and endothelial monolayers during tumor cell metastasis. However, the counterreceptor for E-selectin and its
role in mediating breast cancer cell transendothelial migration remain unknown.
Methodology/Principal Findings: By assessing migration of various breast cancer cells across TNF-a pre-activated human
umbilical vein endothelial cells (HUVECs), we found that breast cancer cells migrated across HUVEC monolayers differentially
and that transmigration was E-selectin dependent. Cell surface labeling with the E-selectin extracellular domain/Fc chimera
(exE-selectin/Fc) showed that the transmigration capacity of breast cancer cells was correlated to both the expression level and
localization pattern of E-selectin binding protein(s) on the tumor cell surface. The exE-selectin/Fc strongly bound to metastatic
MDA-MB-231, MDA-MB-435 and MDA-MB-468 cells, but not non-metastatic MCF-7 and T47D cells. Binding of exE-selectin/Fc
was abolished by removal of tumor cell surface sialyl lewis x (sLe
x) moieties. Employing an exE-selectin/Fc affinity column, we
further purified the counterreceptor of E-selectin from metastatic breast cancer cells. The N-terminal protein sequence and
cDNA sequence identified this E-selectin ligand as a ,170 kD human CD44 variant 4 (CD44v4). Purified CD44v4 showed a high
affinity for E-selectin via sLe
x moieties and, as expected, MDA-MB-231 cell adhesion to and migration across HUVEC monolayers
were significantly reduced by down-regulation of tumor cell CD44v4 via CD44v4-specific siRNA.
Conclusions/Significance: We demonstrated, for the first time, that breast cancer cell CD44v4 is a major E-selectin ligand in
facilitating tumor cell migration across endothelial monolayers. This finding offers new insights into the molecular basis of E-
selectin–dependent adhesive interactions that mediate breast cancer cell transendothelial metastasis.
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Introduction
Metastatic invasion is the primary cause of breast cancer
mortality. A key step in the metastasis process is migration of
tumor cells across the blood vessel-lining endothelial monolayers.
It has been widely reported that endothelial cell E-selectin plays a
pivotal role in mediating cell–cell interactions between tumor cells
and endothelial monolayers during tumor metastasis [1,2,3]. The
major ligand of endothelial E-selectin on the tumor cell surface has
been identified as a sialylated glycan determinant, such as sialyl
Lewis x moieties (sLe
x), which decorate the terminal extensions of
O-linked or N-linked carbohydrates [4]. Interaction of tumor cell
surface sLe
x moieties and sLe
x-decorated glycoproteins with
endothelium E-selectin is a major component of cancer invasion
and metastasis. A positive correlation between expression of E-
selectin ligands such as sLe
x moieties in tumor cells and tumor cell
metastasis or invasion has been widely reported [5,6]. In breast
cancer cells, several studies have also demonstrated a critical role
for E-selectin in regulating tumor cell transendothelial migration
[7,8]. However, the identity of the E-selectin ligand in breast
cancer cells and its physiological contribution in regulating tumor
cell transendothelial migration is unknown.
Several leukocyte adhesion molecules, including leukocyte P-
selectin glycoprotein ligand-1 (PSGL-1) and E-selectin ligand-1
(ESL-1),havebeenidentified asligandsforendothelial E-selectin[9].
These interactions between PSGL-1, ESL-1 and E-selectin play a
significant roleinregulating leukocyterolling process.Dimitroffet al.
[10] reported that both E-selectin binding forms of PSGL-1 and
ESL-1 are expressed on the human bone-metastatic prostate tumor
MDA PCa 2b cell line, suggesting that these molecules may serve as
E-selectin ligands in mediating tumor cell adhesion to or migration
across endothelium. However, it is unclear whether breast cancer
cellsorothernon-bonederivedmetastatictumorcellsexpressPSGL-
1 or ESL-1. Recently, studies have demonstrated that CD44 variant
isoforms (CD44v) in LS174T colon carcinoma cells possess selectin
binding activity [11,12], suggesting a broader role for CD44v in
regulating tumor cell metastasis, particularly the event of migration
across the vascular endothelium. CD44 was originally identified as a
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contains hyaluronic acid (HA)–binding motifs and several potential
glycosylation sites [13]. Through its interaction with hyaluronan,
CD44 serves as an adhesion molecule in cell–substrate and cell–cell
interactions, lymphocyte recruitment to inflammatory sites, and
tumor metastasis [14,15,16,17]. The size of the CD44 molecule
ranges from the standard 85–95 kD form (CD44s) to larger variant
isoforms of 200 kD or more due to RNA splicing and post-
translational modifications [18]. Functional characterization of
different isoforms of the CD44 family, however, is still limited.
Many cancer cell types express high levels of specific variants of
CD44 [19]. The animal model studies have shown that interfering
with the binding of CD44 to its ligand inhibits local tumor growth
and metastatic spread [20,21]. During tumor metastasis, cells detach
from the primary tumor, penetrate the basement membrane into the
connective tissue, and invade adjacent organs structures, including
blood vessels.Tumor cells aresubsequentlytransported to metastatic
sites through the blood stream. However, the mechanisms by which
CD44 modulates the tumor cell transendothelial migration process
are not fully understood.
In the present study, we demonstrated that metastatic breast
cancer cells strongly express a ,170 kD CD44 variant 4 (CD44v4).
The expression level and localization pattern of CD44v4 in breast
cancer cells is closely correlated with tumor cell migratory capability
across TNF-a pre-activated HUVEC monolayers. Our results
further showed that CD44v4 is highly decorated with E-selectin
binding sLe
x moieties and serves as a major adhesive molecule in
mediating breast cancer cell transendothelial metastasis.
Results
Breast cancer cell transendothelial migration is E-selectin
dependent
HUVEC monolayers cultured on collagen-coated permeable
Transwell filters were used as a model for endothelial cell
monolayers to assess the transmigration of breast cancer cells.
HUVEC monolayers were pre-activated with 25 ng/ml TNF-a
for 6 h to upregulate the expression of adhesion molecules before
the tumor migration assay. Five breast cancer cell lines including
MDA-MB-231, MDA-MB-435, MDA-MB-468, T47D, and
MCF-7 were assessed for their migratory capability across
HUVEC monolayers. The general migratory capability of these
five breast cancer cells has been well-studied [15,22–25]. Various
breast cancer cells have a marked differential migratory capability.
Among five cancer cell lines, MDA-MB-231, MDA-MB-435 and
MDA-MB-468 have a higher invasive ability and are generally
regarded as metastatic breast cancer cells while MCF-7 and T47D
cells have a lower invasive ability and are regarded as non-
metastatic cells. As shown in Figure 1A, MDA-MB-231 had the
highest transmigration rate across TNF-a pre-activated HUVEC
monolayers while MDA-MB-435 and MDA-MB-468 cells dem-
onstrated relatively modest transmigration. Compared to these
metastatic breast cancer cells, MCF-7 cells and T47D cells had a
significantly lowertransmigration rate. The transmigration ofMDA-
MB-231, MDA-MB-435 and MDA-MB-468 cross TNF-a pre-
activated HUVEC monolayers was further characterized in the
presence of various functional inhibitory antibodies. As shown in
Fig.1B,migration ofMDA-MB-231cellscrossHUVECmonolayers
was significantly blocked by anti-E-selectin antibody, but not by
inhibitory antibodies against LFA-1 or VLA-4 (Fig. 1B), suggesting
that metastasis of breast cancer cells across TNF-a pre-activated
HUVEC monolayers is specifically dependent on HUVEC E-
selectin. Similar inhibition by anti-E-selectin antibody on tumor cell
transendothelial migration was observed in both MDA-MB-435 and
MDA-MB-468 cell migration assays (data not shown).
Since the migration results suggest that E-selectin plays a critical
role in mediating breast cancer cell transendothelial migration, we
next examined the interactions of breast cancer cells with a soluble
recombinant protein of E-selectin extracellular domain (exE-
selectin/Fc). A direct binding assay of breast cancer cells with
Figure 1. Transendothelial migration of breast cancer cells. A: differential migration of breast cancer cells across HUVEC monolayers pre-
activated with TNF-a. B: migration of MDA-MB-231 across HUVEC monolayers in the presence of anti-E-selectin, anti-ICAM-1, and anti-VLA-4
antibodies (25 mg/ml each), respectively. HUVEC monolayers were pre-incubated with endothelial medium containing 25 ng/ml TNF-a for 6 h, and
migration was terminated after overnight incubation at 37uC. All data are expressed as the mean6SD (n=3) of a typical experiment and similar
results were obtained in at least three separate experiments.
doi:10.1371/journal.pone.0001826.g001
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selectin/Fc or Fc-only (served as a control) was incubated with
non-fixed breast cancer cells at 4uC for 1 h, and bound Fc was
detected by fluorescently conjugated goat anti-rabbit Fc antibody.
As shown in Figure 2, the exE-selectin/Fc recombinant strongly
bound to MDA-MB-231, MDA-MB-435 and MDA-MB-468 cell
surfaces. The Fc-only control did not bind to any breast cancer
cells. In contrast to MDA-MB-231, MDA-MB-435 and MDA-
MB-468 cells, MCF-7 cells showed no significant binding of exE-
selectin/Fc recombinant. A similar negative staining ofexE-selectin/
Fc was observed in T47D cells (data not shown). Since sLe
x moieties
are major binding partners of E-selectin, we further determined
whether the binding of exE-selectin/Fc to metastatic breast cancer
cells was dependant on tumor cell surface sLe
x moieties. As shown in
the figure, removal of sLe
x moieties from the tumor cell surface by
neuraminidase treatment markedly reduced the binding of exE-
selectin/Fc. Taken together, these results suggested that sLe
x
moieties are likely involved in mediating the binding interactions
of breast cancer cells to E-selectin and that breast cancer cell
transendothelial migration is positively correlated to the binding
activity of the exE-selectin/Fc recombinant to tumor cells.
We next determined the localization pattern of E-selectin
binding protein(s) on the breast cancer cell surface. Tumor cells
cultured in tissue culture dishes were directly incubated with
soluble exE-selectin/Fc or Fc-only for 1 h at 4uC. As shown in
Figure 3, MDA-MB-231, MDA-MB-435 and MDA-MB-468 cells
were all strongly labeled with exE-selectin/Fc, while MCF-7 and
T47D were not or only weakly stained. This observation was in
agreement with flow cytometry analysis (Fig. 2). However, among
three metastatic breast cancer cells, the binding patterns of the
exE-selectin/Fc recombinant were strikingly different. On the
surface of highly metastatic MDA-MB-231 cells, exE-selectin/Fc
bound strongly to the migrating front of the cell (arrows),
particularly the ‘‘spiking’’ cellular protrusions (arrowheads). In
contrast, exE-selectin/Fc was found to be concentrated at sites of
cell-cell contact in both MDA-MB-435 and MDA-MB-468 cells,
which had relatively less transmigration compared to MDA-MB-
231 cells (Fig. 1). These results suggested that metastatic breast
cancer cell transendothelial migration might also be correlated to
the localization pattern of E-selectin binding protein(s) on the
tumor cell surface. Co-staining MDA-MB-231 cells with exE-
selectin/Fc recombinant and rhodamine-conjugated phalloidin
showed that F-actin (red, arrows) was predominantly localized at
the exE-selectin/Fc binding region (green, arrows), including the
‘‘spiking’’ cellular protrusions (arrowheads). The co-distribution of
F-actin and the exE-selectin/Fc recombinant in metastatic breast
cancer cells suggests that the E-selectin binding protein(s) were
mainly localized to the leading edge or migrating front of MDA-
MB-231 cells during metastasis.
Figure 2. Binding of soluble exE-selectin/Fc recombinant to
breast cancer cells via sLe
x moieties on the tumor cell surface.
Trypsin-elicited breast cancer cells were surface labeled with soluble
exE-selectin/Fc or Fc-only as detailed in the Methods. The bound Fc
recombinants were detected by Alexa Fluor 488-conjugated goat anti-
rabbit Fc and measured by FACS. In separated experiments, tumor cells
were treated with neuraminidase to remove surface sLe
x moieties
before exE-selectin/Fc binding.
doi:10.1371/journal.pone.0001826.g002
Figure 3. Localization of potential E-selectin ligand(s) on the
breast cancer cell surface. A: After blocking with 5% normal goat
serum in PBS, breast cancer cells cultured in a tissue culture dish were
incubated with exE-selectin/Fc (10 mg/ml) in blocking solution for 1 h at
4uC. Following three washes, cells were fixed with 3.5% paraformalde-
hyde (5 min, 20uC) and the bound exE-selectin/Fc was detected by
Alexa Fluor 488-conjugated anti-rabbit Fc. Cell surface labeling with Fc-
only served as a background control. B: To determine the localization of
E-selectin ligand on metastatic tumor cell surfaces during migration,
MDA-MB-231 cells were double labeled with soluble exE-selectin/Fc for
E-selectin ligand (left panel) and rhodamine-conjugated phalloidin for
F-actin (right panel). Bar, 20 mm.
doi:10.1371/journal.pone.0001826.g003
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sLe
x moieties-decorated membrane glycoprotein that
binds to E-selectin
In order to isolate and identify the E-selectin binding protein(s)
that mediate breast cancer cell adhesion to and migration across
endothelial monolayers, we constructed an affinity column by
immobilizing exE-selectin/Fc to protein A-conjugated Sepharose.
,5610
8 MDA-MB-231 cells were used to obtain sufficient
quantities of E-selectin ligand for microsequence analysis. As
shown in Figure 4A, three major bands around 170 kD, 130 kD
and 50 kD were found in the eluted proteins. Among these three
protein bands, the 50 kD and 130 kD bands were confirmed as
IgG heavy chain and the exE-selectin/Fc recombinant, respec-
tively. Thus, the protein band at 170 kD was selected for further
analysis. The N-terminal peptide sequence of 10 amino acids,
QIDLNITCRFA, from the 170 kD purified protein had a
sequence that 100% matched the matured form of human
CD44, a highly glycosylated membrane protein (Fig. 4B). The
CD44 identity of this glycoprotein was further confirmed by
Western blot analysis against anti-CD44H antibody, which can
recognize all CD44 variants (Fig. 4C). Western blot results also
confirmed that metastatic MDA-MB-231, MDA-MB-435 and
MDA-MB-468 cells all strongly expressed CD44, while non-
metastatic MCF-7 and T47D cells had little CD44 expression.
Since CD44 has multiple variants containing the common N-
and C-terminal region but a different inserted portion within the
extracellular domain due to alternative splicing, the N-terminal
sequence alone can not distinguish which CD44 variant is involved
in mediating breast cancer transendothelial metastasis. To solve
this problem, we amplified the cDNA encoding the CD44
extracellular domain from various breast cancer cells using a pair
of primers, forward primer 59-TATAAGCTTTTCGCTCCG-
GACACCATGGACAAG-39, and reverse primer 59-ATAA-
GATCT TTCTGGAATTTGGGGTGTCCTTAT-39. Since this
pair of primers target the sequence shared by all CD44 variants,
they amplify all variant isoforms of the CD44 protein. As shown in
Figure 5A, a major band around 1.2 kb was observed in MDA-
MB-231, MDA-MB-435 and MDA-MB-468. The DNA sequence
of the 1.2 kb PCR product indicated that it was CD44 variant 4
(CD44v4) (gene accession number: NM001001391). No PCR
product was amplified from either MCF-7 or T47D cells.
Interestingly, a slightly larger PCR product was amplified from
colonic HT29 cells using the same primers, and its sequence
matched that of CD44 variant 3 (CD44v3) (gene accession
number: NM001001390). To confirm CD44v4 identification by
PCR, we blotted the 170 kD purified protein with a panel of
monoclonal antibodies that specifically react with different variants
of human CD44. As shown in Figure 5B, Western blot analysis
confirmed the 170 kD protein as CD44v4 (Fig. 5B). Blotting the
170 kD protein band with anti-sLe
x moieties antibody also showed
that this CD44 variant isoform was decorated with sLe
x moieties.
Figure 5C shows the specific binding of purified CD44v4 to exE-
selectin/Fc and that this binding occurred through sLe
x moieties
on CD44v4.
CD44v4 serves as a major E-selectin ligand in mediating
breast cancer cell transendothelial metastasis
To characterize the role of CD44v4 in mediating breast cancer
cell transendothelial migration, we next examined the effects of
CD44v4 knockdown as well as removal of tumor cell surface sLe
x
moieties on tumor cell adhesion to and migration across TNF-a
pre-activated HUVEC monolayers. CD44v4 knockdown in breast
cancer cells was achieved by transfecting MDA-MB-231 cells with
CD44v4 siRNA [26]. As shown in Figure 6A, Western blot
analysis demonstrated that the CD44v4 expression level was
significantly decreased in MDA-MB-231 cells after CD44v4
siRNA transfection. However, CD44v4 protein level was not
changed in MDA-MB-231 cells transfected with control oligonu-
Figure 4. Identification of the major E-selectin binding protein in metastatic breast cancer cells as human CD44. A: Gel-code staining
of proteins eluted from an exE-selectin/Fc affinity column. A 170 kD protein indicated by the arrow was selected as a potential ligand of E-selectin in
tumor cells since 130 kD and 50 kD protein bands were confirmed as exE-selectin/Fc and IgG heavy chain, respectively. B: matching of the 10 amino
acid N-terminal peptide sequence (red) of the 170 kD purified protein with that of human CD44. C: Western blot analysis of five breast cancer cell
lines with anti-CD44H antibody.
doi:10.1371/journal.pone.0001826.g004
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after CD44v4 siRNA transfection was also shown by cell surface
immunofluorescence labeling (Fig. 6B). Interestingly, CD44v4
siRNA transfection not only decreased the CD44v4 protein level
on the MDA-MB-231 cell surface, but also changed tumor cell
morphology. As can be seen in figure 6B, mock–transfected MDA-
MB-231 cells maintained their typical spindle shape and had
numerous ‘‘spiking’’ protrusions brightly labeled with anti-CD44H
antibody (arrowheads). In contrast, in CD44v4 siRNA–transfected
MDA-MB-231 cells, no anti-CD44H antibody labeled ‘‘spiking’’
cellular protrusions were observed, and tumor cells had lost their
long spindle shape. The E-selectin binding and transmigration
capacity of MDA-MB-231 cells before and after CD44v4
downregulation was further determined. As shown in Figure 6C,
mock-transfected MDA-MB-231 cells strongly adhered to immo-
bilized exE-selectin/Fc, with an adhesion rate of 79.5610.2% of
the total applied cells. However, the adhesion of CD44v4 siRNA-
transfected MDA-MB-231 cells was significantly decreased, with
an adhesion rate of 31.267.4%. The adhesion rate of CD44v4-
downregulated MDA-MB-231 cells was close to that of MDA-MB-
231 cells pretreated with neuraminidase (21.464.2%). Similar
results were observed in adhesion assays using TNF-a pre-
activated HUVEC monolayers instead of immobilized recombi-
nant exE-selectin/Fc (Fig. 6D). CD44v4 siRNA–transfected
MDA-MB-231 cells also showed a marked reduction in transmi-
gration across TNF-a pre-activated HUVEC monolayers. As
shown in Figure 6E, after overnight incubation, transendothelial
migration of MDA-MB-231 cells transfected with CD44v4 siRNA
was reduced to only one third of that of mock-transfected MDA-
MB-231 cells.
Discussion
Breast carcinoma is one of the most common tumors recently
found in female patients, and its metastasis is a major cause of death.
Although the metastasis of breast cancer cells is a complex process
that requires the activity of multiple genes including urokinase
plasminogen activator, cytokines, chemokines, and matrix metallo-
proteinases (MMPs) [27,28,29], it has been widely reported that the
selectin family of adhesion molecules and their ligands play a critical
role in tumor cell metastasis through blood vessels [1,2,3]. During
tumor cell metastasis, binding interactions generally occurred
between selectin-expressed endothelial cell monolayers and selectin
ligands on tumor cells. The binding capacity of tumor cells to blood
vessel-lining endothelium through E-selectin was closely correlated
to the metastatic capability of breast cancer cells. A previous study
demonstrated that E-selectin ligation regulated the transendothelial
migration of colon cancer cells via mediating p38 and ERK MAP
kinase activation [30]. However, E-selectin ligands expressed in
migrating tumor cells, particularly breast cancer cells, are not well-
characterized. In the present study, we show that the CD44 variant
isoform 4 (CD44v4) is a major metastatic breast cancer cell
glycoprotein decorated with sLe
x moieties and serves as an E-
selectin ligand in facilitating tumor cell migration across TNF-a pre-
activated HUVEC monolayers.
CD44v4 mediates breast cancer cell adhesion to
endothelial monolayers via interacting with E-selectin
In the present study, the binding activity of breast cancer cells to
E-selectin was carefully characterized at the cellular level. Using
soluble E-selectin/Fc recombinant as a probe, we directly detected
Figure 5. Identification of the CD44 variant isoform in metastatic breast cancer cells as CD44v4. A: RT-PCR amplification and DNA
sequence of CD44 extracellular domain from various breast cancer cells and colonic HT29 cells. B: Western blot analysis of the 170 kD purified protein
with antibodies specific to sLe
x moieties and different CD44 variant isoforms, respectively. C: Specific binding of the 170 kD purified protein (CD44v4)
to E-selectin through sLe
x moieties. The data are represented as the mean6SD of three different experiments.
doi:10.1371/journal.pone.0001826.g005
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clearly demonstrated a positive correlation between the binding
activity of soluble E-selectin/Fc recombinant and the ability of
breast cancer cells to migrate across endothelial cell monolayers.
Firstly, E-selectin binding protein(s) are abundantly expressed in
metastatic breast tumor cells including MDA-MB-231, MDA-MB-
435 and MDA-MB-468, but not in non-metastatic tumor cells
such as MCF-7 and T47D (Fig. 2 and Fig. 3). Secondly, labeling of
E-selectin/Fc recombinant on the breast cancer cell surface also
demonstrated a strikingly different pattern among various
metastatic tumor cells. As shown in Figure 3, in MDA-MB-231
cells, which had the highest transmigration rate across TNF-a pre-
activated HUVECs, the E-selectin/Fc recombinant strongly
bound to the migrating cell front, particularly the ‘‘spiking’’
structures of cell protrusions. In contrast, in MDA-MB-435 and
MDA-MB-468 cells, which had relative lower transmigration rates
compared to MDA-MB-231 cells, binding of the E-selectin/Fc
recombinant was mainly found at sites of cell-cell contacts. Taken
together, these results suggest that breast cancer cell transendothe-
lial migration is closely correlated to both the expression level and
localization pattern of cell surface E-selectin binding protein(s). In
the present study, we selected HUVEC as a model endothelial cell
line to characterize the interactions between breast cancer cells
and endothelial monolayers during tumor metastasis is mainly due
to the simplicity of HUVEC system. However, for better
understanding breast tumor cell migration across blood vessel-
lining endothelium under pathophysiologic conditions, primary
cultured endothelial cells that are isolated from particular blood
vessels should be used. Moreover, in order to mimic the real
physiological situation of tumor metastasis, tumor cell transmigra-
tion across HUVEC monolayers pre-activated by TNF-a should
be also measured under flow condition.
The binding of the E-selectin/Fc recombinant to metastatic
breast cancer cells was largely reduced by removal of sLe
x moieties
from tumor cell surfaces (Fig. 2 and Fig. 6C), suggesting that the E-
selectin binding protein(s) in metastatic breast cancer cells are
decorated with sLe
x moieties and that sLe
x moieties play a
significant role in mediating tumor cell binding to E-selectin.
Considering that sLe
x moieties are major E-selectin binding
partner [31], this finding was not surprising. It is well-known that
sLe
x moieties can mediate adhesion of tumor cells to the
endothelium via interactions with E-selectin. In normal breast
tissues, the expression levels of sLe
x moieties and sLe
x moiety-
decorated glycoproteins are very low. However, up-regulation of
sLe
x moiety expression has been widely reported to be correlated
with poor prognosis and malignant relapse [5,6].
By using an affinity column constructed by immobilizing E-
selectin/Fc recombinant, the E-selectin binding protein that
mediated breast cancer cell transendothelial migration was
identified as human CD44 (Fig. 4). Further analysis based on
RT-PCR and Western blot indicated it as CD44 variant 4
(CD44v4) (Fig. 5). As a multistructural and multifunctional cells
surface adhesion molecule, CD44 is involved in cell-cell and cell-
matrix interactions [13,16]. There are multiple ligands of CD44,
including the extracellular matrix (ECM) components collagen
[32], fibronectin [33], laminin [34], chondroitin sulfate [35] and,
particularly, hyaluronic acid (HA) [18]. Through binding all of
these ligands, CD44 plays a critical role in initiating the metastatic
spread of tumor cells [16,36,37]. Structurally, the genomic
organization of CD44 is composed of twenty exons. Besides the
first five and last five constant exons, there are 10 exons located
between these regions that are subjected to alternative splicing,
resulting in the generation of a variable region. Differential
utilization of the 10 variable region exons, as well as variations in
Figure 6. The role of CD44v4 in mediating breast cancer cell adhesion and transmigration. A and B: siRNA transfection-induced CD44v4
downregulation in MDA-MB-231 cells as shown by Western blot (A) and immunofluorescence labeling (B), respectively. C and D: reduction of MDA-
MB-231 cell adhesion to immobilized recombinant exE-selectin/Fc (C) and TNF-a pre-activated HUVEC monolayers (D) after CD44v4 downregulation
via siRNA. E: reduction of MDA-MB-231 cell transendothelial migration by CD44v4 downregulation. The data are representative of three independent
experiments.
doi:10.1371/journal.pone.0001826.g006
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sulfate or chondroitin sulfate), generates multiple CD44 isoforms.
These isoforms have various tissue specificity and ligand binding
activity. Some CD44 isoforms have been found to play an essential
role in tumor progression [38]. Here, for the first time, our results
demonstrate that CD44v4 is a major CD44 isoform expressed in
metastatic breast cancer cells, and this CD44 variant is a
membrane glycoprotein decorated with E-selectin binding sLe
x
moieties.
CD44v4 mediates breast cancer migration across
endothelial cell monolayers
High levels of various CD44 variants (CD44v) are widely found
in metastatic breast carcinoma [19,38,39]. This is confirmed by
our observation that three metastatic breast carcinoma cell lines,
MDA-MB-231, MDA-MB-435 and MDA-MB-468, expressed
high levels of CD44v4 (Fig. 4 and 5). A number of lines of
evidences have implicated CD44v with a possible role in tumor
progression [40,41]. However, how each CD44v contributes to the
malignant phenotype, particularly the transmigration event of
breast cancer cells across the endothelial monolayers lining the
blood vessels, is largely unknown. Herrera-Gayol and Jothy [42]
showed that CD44 variants (especially CD44v6) could regulate the
binding of breast cancer cells to extracellular HA, and these
binding interactions could mediate tumor cell metastasis. Recent-
ly, Napier et al [12] demonstrated that the LS174 colon carcinoma
cell CD44 variant bound to selectin through sialidase-sensitive O-
linked glycans presented on CD44. Here, we present evidence that
CD44v4 is a major E-selectin ligand expressed in metastatic breast
cancer cells, and plays a critical role in regulating tumor cell
transendothelial invasion. In addition, binding of the E-selectin/Fc
recombinant to the migrating front and particularly the ‘‘spiking’’
protrusions of MDA-MB-231 cells (Fig. 3) suggest that CD44v4
may be a key component of the tumor cell migration machinery.
CD44v4 is likely involved in reorganization of the cell cytoskeleton
during cell directional movement since CD44 variants can strongly
associate with actin microdomains and ERM proteins [43].
CD44v4 may also regulate breast cancer cell transendothelial
metastasis by functioning not only as an adhesive receptor for E-
selectin, but also as a signaling transducer. It has been reported
that phosphorylation of the CD44 isoform is required in tumor cell
directional sensing of a phorbol ester gradient during invasion
[44]. Engagement of CD44 has also been shown to induce protein
kinase C and Rac activation during cell migration [45]. By
pretreating breast cancer cells with a cross-linking reagent such as
anti-CD44 antibody, Wang et al [15] reported that ligation of
tumor cell surface CD44 enhanced tumor cell transendothelial
migration by increasing the expression of lymphocyte function-
associated antigen-1 (LFA-1) and very late antigen 4 (VLA-4).
Similar up-regulation of tumor cell integrins and integrin-
mediated adhesion by CD44 ligation was also found in a colon
cancer cell line [46]. One possible mechanism by which CD44
ligation enhances integrin expression and tumor cell adhesion is
through up-regulation of c-Met [46]. In the present study,
however, we did not find a significant inhibitory role for either
anti-LFA-1 antibody or anti-VLA-4 antibody during CD44v4-
mediated breast cancer cell migration across TNF-a pre-activated
HUVEC monolayers (Fig. 1), strongly arguing for a minor role of
leukocyte-specific integrins in breast cancer cell metastasis.
In summary, the present study has demonstrated that CD44v4 is
a major E-selectin ligand expressed in metastatic breast cancer cells
and plays an essential role in regulating tumor cell adhesion to and
migration across endothelial monolayers. The results expand our
present knowledge of E-selectin-based tumor cell transendothelial
metastasis, which might shed some light on the search for new
pharmacological approaches to control breast tumor metastasis.
Materials and Methods
Cells
The human breast carcinoma cell lines, MDA-MB-231, MDA-
MB-435S, MDA-MB-468, T47D, and MCF-7 were obtained from
Dr.PaulWade(DepartmentofPathologyandLaboratoryMedicine,
Emory University, Atlanta) and Dr. Xiao Han (Nanjing Medical
University, Nanjing, China). Breast cancer cells were grown in
Dulbecco’s modified Eagle’s medium (Gibco BRL, Grand Island,
NY) supplemented with 10% fetal bovine serum (Hyclone, Logan,
UT), 100 units/ml penicillin and 100 mg/ml streptomycin. Human
umbilical vein endothelial cells (HUVECs) were purchased from the
China Cell Culture Center (Shanghai, China) and cultured in
endothelial medium (Clontech, Mountain View, CA) supplemented
with penicillin-streptomycin (100 U/ml and 100 mg/ml, respective-
ly). All media werereferred to as complete medium and all of the cell
lines used in the study were free of Mycoplasma.
Antibodies and Reagents
The monoclonal antibodies used in the experiments and their
resources: mouse anti-human E-selectin mAb (MAB575), mouse
anti-human CD44H (clone 2C5), mouse anti-human CD44v3
(clone 3G5), mouse anti-human CD44v6 (clone 2F10) and mouse
anti-human CD44v4/5 (clone 3D2) (R&D Systems, Minneapolis,
MN); Anti-CD44v4 mAb (Lab Vision, Fremont, CA); Anti-human
LFA-1 and anti-human VLA-4 mAbs (BD Pharmingen, San
Diego, CA); Anti-sLe
x mAb (Clone KM93) (Chemicon, Temecula,
CA); HRP-conjugated goat anti-mouse and anti-rabbit IgG
(Jackson ImmunoResearch Lab, West Grove, PA); Alexa Fluor
488(495/519) and Alexa Fluor 568(578/603)-conjugated second-
ary antibodies (Molecular Probes, Eugene, OR). BCECF-AM,
rhodamine-conjugated phalloidin and ProLong antifade reagent
were also obtained from Molecular Probes. TNF-a was purchased
from Genetech (South San Francisco, CA).
Soluble Human E-selectin-Fc Chimera Preparation
cDNA encoding the human E-selectin extracellular domain
(residues 1-556) [47] was amplified from a human colon cDNA
library (Clontech) by PCR using forward primer 59-ATAT
CATATGAAAAGAACTCTTGAAGTCATG-39 and reverse
primer 59-ATATAGATCTAGCTTCACAGGTAGGTAGCAG-
39. The cDNA encoding the E-selectin extracellular domain was
fused to a modified rabbit IgG1 Fc region and cloned into
pcDNA3.1 (Invitrogen, Carlsbad, CA) using the NdeI/HpaI
digestion site. COS-7 cells were used for transfection and fusion
protein generation [48]. E-selectin/Fc was affinity purified from
cell culture supernatants by Protein A-Sepharose (Sigma, St.
Louis, MO) and eluted with 100 mM glycine/HCl, pH 3.5,
immediately followed by neutralization, concentration and
dialysis. As a control, the Fc portion of the fusion protein was
also prepared [48]. Commercial Recombinant Human E-selectin/
CD62E/Fc chimera was obtained from R&D Systems.
Immunofluorescence and Flow Cytometric Analysis
For breast cancer cell surface labeling with soluble exE-selectin/
Fc, cells grown to confluence on a culture dish were washed three
times with cold HBSS and blocked with 5% normal goat serum in
HBSS for 30 min on ice. Soluble exE-selectin/Fc and Fc-only
(10 mg/ml each) were dissolved in blocking buffer and added to
the cell culture dishes. After 1 h incubation on ice, cells were
washed three times with HBSS and fixed with 3.7% paraformal-
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detected by fluorescence conjugated goat anti-rabbit Fc antibody.
In some experiments, cells labeled with exE-selectin/Fc were
further permeabilized with 0.03% Triton X-100 (5 min, 4uC) and
stained with rhodamine conjugated phalloidin (30 min, 4uC). After
extensive washing, labeled cells were then mounted in ProLong
antifading embedding solution and analyzed using a fluorescence
microscope equipped with an imaging system (Olympus, Japan). A
1006NA/1.3 Plan-Neofluar oil immersion lens (Olympus) was
used for all images. Images shown are representative of at least
three experiments, with multiple images taken per slide. As a
control for background labeling, cells were incubated with
comparable concentrations of irrelevant IgG and secondary
antibody. For flow cytometric analysis, suspended tumor cells
(1610
7 cells; 1 ml) incubated with E-selectin/Fc fusion protein or
Fc only were fixed and then incubated for 45 min at 4uC with
Alexa Fluor 488-conjugated antibody solution (1:1000 dilution).
After three washes, cells were re-suspended and flow cytometry
analysis was performed on a FACS instrument. The results were
analyzed using CELLQUEST software (BD Biosciences).
E-selectin Ligand Purification and Identification
An affinity column was constructed by immobilizing exE-selectin/
Fc to protein A-conjugated Sepharose beads. ,500 cm
2 of confluent
MDA-MB-231cellswereusedforE-selectinligandisolation.Proteins
were eluted from the affinity column at low pH (150 mM NaCl,
100 mM glycine/HCl, pH 3.5, containing 1% n-octylglucoside).
The eluant was pH-neutralized and resolved by 10% SDS-PAGE,
and the protein bands were visualized by Gelcode 250 staining. The
resulting ,170 kD protein band (,100 pmol) was extracted and
subjected to direct N-terminal protein sequence analysis.
Western Blotting
Cell lysates were homogenized in loading sample buffer,
normalized for total protein, and loaded on 10% SDS-PAGE
gels. After electrophoresis and transfer onto Hybond nitrocellulose
membranes (Amersham, Piscataway, NJ), membranes were
blocked with 5% non-fat milk in TTBS, incubated with primary
antibody followed by incubation with horseradish peroxidase–
conjugated secondary antibody and ECL detection (Amersham).
The sLe
x moieties were detected by mouse anti-sLe
x antibody,
while CD44v was detected using a panel of monoclonal antibodies
against various CD44 isoforms including CD44H, respectively.
siRNA Experiment
The CD44v4 siRNA experiment was performed as previously
described [26]. CD44v4 siRNA oligonucleotides, antisense 59-
UAUAUUCAAAUCGAUCUGCTT-39 and sense 59-GCA-
GAUCGAUUUGAAUAUATT-39 (GC Content: 31.6%, position
494), were obtained from Sigma. Briefly, annealed siRNA oligo-
nucleotides were transfected into MDA-MB-231 cells seeded in
tissueculture plates(35–50%confluent) with 100 mM Lipofectamine
2000 (Invitrogen) in Opti-MEM reduced-serum medium (Invitro-
gen) [26]. Cells were incubated at 37uC for 4 hours before addition
of complete medium and cultured for an additional 72 hours before
further assays. In the mock transfection control group, oligonucle-
otides (59-UCUACUCUUCCUUCUGCAACCCTT-39 and 59-
GGGUAGCAGAA GGAGUAGATT-39) (Sigma) were used.
Protein Binding Assay
Purified CD44v4 protein (,150 mg/ml in the final solution
containing 1% n-octylglucoside) was diluted 1:20 with PBS and
50 ml of diluted solution was immediately added to each well of a
96-well microtiter plate (Costar, Cambridge, MA). Plates were
incubated overnight at 4uC to allow protein immobilization. Wells
coated with 1% BSA served as controls. After blocking with 1%
BSA, plates were incubated with exE-selectin/Fc or Fc only (5 mg/
ml each) in blocking solution for 1 h at 37uC. After three washes,
bound Fc recombinant was detected by HRP-conjugated goat
anti-rabbit Fc antibody and OD measurement. In some
experiments, immobilized CD44v4 was treated with neuramini-
dase for 30 min at 37uC to remove sLe
x moieties prior to the Fc-
recombinant binding assay.
Cell Adhesion Assay
The adhesion assay was performed in 96-well plates as
previously described [46,49,50]. For cells adhesion to immobilized
recombinant E-selectin, 100 ml exE-selectin/Fc or Fc-only (20 mg/
ml each) was added to a 96-well microtiter plate and incubated
overnight at 4uC to allow protein immobilization. Plates were then
blocked with 1% BSA in HBSS for 30 min. For cell adhesion to
HUVEC monolayers, 2610
5 HUVECs cells were grown to
confluence on collagen-coated Transwell membranes, and then
treated for 6 h with 25ng/ml TNF-a [51,52]. Suspended breast
cancer cells were pre-labeled with 2.5 mM BCECF-AM for 10 min
at 37uC. After three washes, cells were re-suspended in HBSS
containing 1% BSA at a concentration of 2610
5 cells/ml. 150 ml
of the cell suspension was added to 96-well plates or the upper
chamber of Transwell setups. After 1 h incubation in the presence
of various antibodies at 25 mg/ml each, plates and Transwell
filters were washed three times to remove unbound tumor cells.
The fluorescence of plates was read directly on a Fluorescence
Measurement System (Millipore, Cytofluor 2300) at wavelengths
of 485/538 nm excitation/emission. For Transwell setups, cells
were elicited by trypsin/EDTA and re-suspended in 150 ml HBSS
for fluorescence measurement.
Transmigration assay
Transendothelial migration assays of breast cancer cells were
performed as described previously with a minor modification [53].
Briefly, 5.0 mm pore-size Transwell filters were coated with rat
collagen at a concentration of 150 mg/cm
2 by drying overnight
under a laminar flow hood. HUVECs were seeded onto
rehydrated coated membranes at a concentration of 2610
5
cells/well. After confluent monolayer formation, HUVEC mono-
layers were treated with 25 ng/ml TNF-a for 6 h [51,52].
Invasion assays of breast cancer cells were performed by applying
approximately 10
6 disaggregated cells to the upper reservoir. The
invasion medium was placed in the wells on both sides of the
membranes. Invasion assays were incubated overnight at 37uC
and, thereafter, HUVEC monolayers and non-invading cells on
the upper surface of the membrane were removed. Migrated
tumor cells on the bottom side of the membranes and in the lower
chamber were collected, stained and calculated under a micro-
scope [15].
Statistics
The data are expressed as the mean6SD of at least three
experiments performed in quadruplicate. Statistical analysis of the
significance of differences between groups was carried out using a
Student’s t test. A p,0.05 was considered significant.
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